Respimat
Drug delivery device used for the treatment of respiratory conditions
Respimat, also known as Respimat Soft Mist Inhaler, is a drug delivery device used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Its developer, Boehringer Ingelheim, is currently[when?] conducting approved in the U.S. with a variety of their products, such as tiotropium and ipratropium/salbutamol. According to the manufacturer, the reusability of the inhaler reduces its carbon footprint by 71%.[1]
References
- ^ "First reusable, propellant-free inhaler launched to cut plastic waste". Pharmaceutical Journal. 17 September 2019. Retrieved 19 November 2019.
Sources
- Home — Respimat International
- v
- t
- e
Routes of administration, dosage forms
Digestive tract (enteral) |
| |||||||
---|---|---|---|---|---|---|---|---|
Oral mucosa (buccal, sublabial, sublingual) |
| |||||||
Respiratory tract (inhalation) |
|
otic, nasal
- Nasal spray
- Ear drops
- Eye drops
- Ointment
- Hydrogel
- Insufflation
- Mucoadhesive microdisc
- Parenterals
- Injections
- infusions
(into tissue/blood)
Skin (transdermal) | ||
---|---|---|
Organs | ||
Central nervous system |
| |
Circulatory, musculoskeletal |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e